CinCor Pharma, Inc. Common Stock
CINC
CINC was delisted on the 23rd of February, 2023.
57 hedge funds and large institutions have $596M invested in CinCor Pharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
15% more capital invested
Capital invested by funds: $520M → $596M (+$75.8M)
8% more funds holding
Funds holding: 53 → 57 (+4)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.3M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.33M |
| 3 |
JP Morgan Chase
New York
|
+$3.62M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.38M |
| 5 |
BlackRock
New York
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.74M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$1.32M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$751K |
| 4 |
PHK
Point72 Hong Kong
Hong Kong
|
-$387K |
| 5 |
D.E. Shaw & Co
New York
|
-$334K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
51
Ameritas Investment Partners
Lincoln,
Nebraska
| $16K | – | – | – |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $16K | +$7.29K | +381 | +85% |
|
53
Barclays
London,
United Kingdom
| $13K | -$23.2K | -1,212 | -64% |
|
54
Wells Fargo
San Francisco,
California
| $3K | -$45.3K | -2,364 | -93% |
|
55
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $2K | +$2.09K | +109 | New |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$18K | -938 | -93% |
|
|
GWS
57
Glassman Wealth Services
Vienna,
Virginia
| $1K | +$862 | +45 | New |
|
|
CCM
58
CAAS Capital Management
New York
| – | -$1.32M | -75,000 | Closed |
|
|
PHK
59
Point72 Hong Kong
Hong Kong
| – | -$387K | -22,064 | Closed |
|
|
DKCM
60
Davidson Kempner Capital Management
New York
| – | -$262K | -15,000 | Closed |
|
61
Millennium Management
New York
| – | -$210K | -12,000 | Closed |
|
CINC Hedge Fund Activity: Q2 2022 in Review
57 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q2 2022, worth a combined $596M — up 15% from $520M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CINC positions and 4 closed out — a net gain of 5 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Great Point Partners, adding an estimated $11.3M. The largest seller was BVF Inc, cutting an estimated $1.74M.
- 57 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q2 2022, up from 53 in Q1 2022.
- Funds reported $596M of CinCor Pharma, Inc. Common Stock stock for Q2 2022, up 15% quarter-over-quarter.
- 9 funds opened new CinCor Pharma, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of +5 holders.
- The largest CinCor Pharma, Inc. Common Stock buyer in Q2 2022 was Great Point Partners, an estimated $11.3M added.
- The largest CinCor Pharma, Inc. Common Stock seller in Q2 2022 was BVF Inc, an estimated $1.74M sold.
Based on aggregated 13F filings for Q2 2022.